Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

which Sage and Biogen had also applied to market it as a treatment for. In its recent third-quarter earnings call, Sage said the two Cambridge companies would not pursue further development of ...

Biogen has made a further push into RNA-based ... RNA sequencing data to discover new drug targets and therapeutics. Cambridge, Massachusetts-based Envisagenics focuses on using AI to analyse ...

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD ...

Biogen Inc.'s stock shed early gains to trade ... and that overall product revenue was about $80 million below consensus. The Cambridge, Mass.-based company (BIIB) had net income of $388.5 million ...

Biogen Inc. (NASDAQ:BIIB) the central nervous system disease drug developer based in Cambridge Massachusetts, reported its Q3 earnings yesterday, Wednesday, October 30. First, let's look at some ...

CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as Chief Medical Officer and Head of ...

the Cambridge, Massachusetts-based company said Wednesday in a statement. While that’s a 6% decline from a year earlier, it beat analysts’ estimates. The results could help Biogen start to ...

Biogen, Inc. is a biopharmaceutical company ... and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.